www.praktickelekarenstvi.cz e35 / Klin Farmakol Farm 2022;36(1):29-33 / PRAKTICKÉ LÉKÁRENSTVÍ NEMOCNIČNÍ LÉKÁRENSTVÍ Fyzikálně-chemické vlastnosti kolistinu a jejich dopady do klinické praxe LITERATURA 1. Bergen PJ, Li J, Rayner CR, Nation RL. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006;50(6):19531958. 2. Bialvaei AZ, Samadi Kafil H. Colistin, mechanisms and prevalence of resistance. Curr Med Res Opin. 2015;31(4):707-721. 3. Warren HS, Kania SA, Siber GR. Binding and neutralization of bacterial lipopolysacchari‑ de by colistin nonapeptide. Antimicrob Agents Chemother. 1985;28(1):107-112. 4. Velkov T, Thompson PE, Nation RL, Li J. Structure--activity relationships of polymyxin an‑ tibiotics. J Med Chem. 2010;53(5):1898-1916. 5. Sampson TR, Liu X, Schroeder MR, Kraft CS, Burd EM, Weiss DS. Rapid killing of Acineto‑ bacter baumannii by polymyxins is mediated by a hydroxyl radical death pathway. Anti‑ microb Agents Chemother. 2012;56(11):5642-5649. 6. Ehrentraut SF, Muenster S, Kreyer S et al. Extensive Therapeutic Drug Monitoring of Co‑ listin in Critically Ill Patients Reveals Undetected Risks. Microorganisms. 2020;8(3):415. 7. Westerman EM, Le Brun PP, Touw DJ, Frijlink HW, Heijerman HG. Effect of nebulized coli‑ stin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study. J Cyst Fibros. 2004;3(1):23-28. 8. McCoy KS. Compounded colistimethate as possible cause of fatal acute respiratory di‑ stress syndrome. N Engl J Med. 2007;357(22):2310-2311. 9. Abdellatif S, Trifi A, Daly F, Mahjoub K, Nasri R, Ben Lakhal S. Efficacy and toxicity of ae‑ rosolised colistin in ventilator-associated pneumonia: a prospective, randomised trial. Ann Intensive Care. 2016;6(1):26. 10. Lu Q, Luo R, Bodin L et al. Efficacy of high-dose nebulized colistin in ventilator-asso‑ ciated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acineto‑ bacter baumannii. Anesthesiology. 2012;117(6):1335-1347. 11. Wallace SJ, Li J, Rayner CR, Coulthard K, Nation RL. Stability of colistin methanesulfo‑ nate in pharmaceutical products and solutions for administration to patients. Antimicrob Agents Chemother. 2008;52(9):3047-3051. 12. Healan AM, Gray W, Fuchs EJ, Griffiss JM, Salata RA, Blumer J. Stability of colistimethate sodium in aqueous solution. Antimicrob Agents Chemother. 2012;56(12):6432-6433. 13. Bihan K, Zahr N, Becquemin MH et al. Influence of diluent volume of colistimethate so‑ dium on aerosol characteristics and pharmacokinetics in ventilator-associated pneumonia caused by MDR bacteria. J Antimicrob Chemother. 2018;73(6):1639-1646. 14. Dodd ME, Abbott J, Maddison J, Moorcroft AJ, Webb AK. Effect of tonicity of nebuli‑ sed colistin on chest tightness and pulmonary function in adults with cystic fibrosis. Tho‑ rax. 1997;52(7):656-658. 15. Schoeffel RE, Anderson SD, Altounyan RE. Bronchial hyperreactivity in response to in‑ halation of ultrasonically nebulised solutions of distilled water and saline. Br Med J (Clin Res Ed). 1981;283(6302):1285-1287. 16. Boisson M, Jacobs M, Grégoire N et al. Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients. Antimicrob Agents Chemo‑ ther. 2014;58(12):7331-7339. 17. Tsuji BT, Pogue JM, Zavascki AP et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), Eu‑ ropean Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Disea‑ ses Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10-39. 18. Colomycin. Souhrn údajů o přípravku. Státní ústav pro kontrolu léčiv [online]. [cit. 202201-19]. Dostupné z: https://www.sukl.cz. 19. Abdulla A, van Leeuwen RWF, de Vries Schultink AHM. Stability of colistimethate sodi‑ um in a disposable elastomeric infusion device. Int J Pharm. 2015;486:367-369. 20. Post TE, Kamerling IMC, van Rossen RCJM et al. Colistin methanesulfonate infusion so‑ lutions are stable over time and suitable for home administration. European Journal of Hospital Pharmacy. 2018;25:337-339. 21. Michalopoulos A, Kasiakou SK, Rosmarakis ES, Falagas ME. Cure of multidrug-resistant Acinetobacter baumannii bacteraemia with continuous intravenous infusion of colistin. Scand J Infect Dis. 2005;37(2):142-145. 22. Kassamali Z, Curello J, Gregson A. Comparison of continuous versus intermittent intra‑ venous infusion of colistimethate sodium (colistin) for treatment of carbapenem-resistant gram negative bacterial infections. 26th European Congress of Clinical Microbiology and Infectious Diseases. 2012, April 9-12. Amsterdam, Netherlands. 23. Plachouras D, Karvanen M, Friberg LE et al. Population pharmacokinetic analysis of co‑ listin methanesulfonate and colistin after intravenous administration in critically ill pati‑ ents with infections caused by gram-negative bacteria. Antimicrob Agents Chemother. 2009;53(8):3430-3436. 24. Mohamed AF, Karaiskos I, Plachouras D et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother. 2012;56(8):4241-4249.
RkJQdWJsaXNoZXIy NDA4Mjc=